PGL
Click for more information
0.00% 85.0¢ prospa group limited.

Bayer says Nexavar phase III skin cancer tests fail to meet...

  1. retorn123
    701 Posts.
    clock Created with Sketch.
    05/10/07
    15:27
    Post #: 2867732
    Bayer says Nexavar phase III skin cancer tests fail to meet primary endpoint

    bayer LEVERKUSEN, Germany (AFX) - Bayer (nyse: BAY ) AG and Onyx Pharmaceuticals Inc said Phase III skin cancer tests of their Nexavar (sorafenib) tablets failed to meet their primary endpoint of improving progression-free survival (PFS).
    PGL Price at posting: 0.0¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
watchlist Created with Sketch. Add PGL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.